Market reviews

Published on 19 July 2021

Review of the Finnish human pharmaceuticals market

Finland is the most important individual market for Orion, generating more than a quarter of the Group's net sales. According to Pharmarket statistics (1–6/2021), the total sales of Orion's human pharmaceuticals in January-June 2021, including both medicinal and non-medicinal products, were at the previous year's level. The prevalence of seasonal illnesses such as common respiratory tract infections has been lower than normal due to which the market volumes were lower than normal especially in the self-care products.

Orion's biggest product group in Finland are reference-priced prescription drugs in the pharmacy channel. The sales of Orion's reference-priced prescription drugs increased, while the total market fell from the comparison period. The average price of reference-priced drugs in the market declined by approximately 8% from the comparative period (Source: Pharmarket). The impact of constant price competition on Orion has been significant due to the Company's broad product range and significant market share in Finland.

Despite the challenging operating environment, Orion has maintained its position as leader in marketing pharmaceuticals in Finland. Orion has a particularly strong position in reference-priced prescription drugs and self-care products, with its market share being a quarter of the market in each. 

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

EUR million

 

1-6/21

1-6/20

Change %

Total sales of human pharmaceuticals (hospital and pharmacy channel)

 

 

 

Market

 

1,426

1,421

+0%

Orion

 

154

154

+0%

Prescription drugs total (pharmacy channel)

 

 

 

 

Market

789

782

+1%

Orion

89

87

+2%

Reference priced prescription drugs (pharmacy channel) *

 

Market

215

228

-6%

Orion

51

50

+2%

Self-care products (pharmacy channel)

 

Market

 

197

207

-5%

Orion

 

49

53

-7%

 

* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.  

Source: Pharmarket sales statistics 1-6/2021

 

Orion’s market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

Orion’s market share, %

1-6/21

1-6/20

Human pharmaceuticals in total (hospital and pharmacy channel)

11%

11%

Prescription drugs total (pharmacy channel)

11%

11%

Reference priced prescription drugs (pharmacy channel) *

24%

22%

Self-care products (pharmacy channel)

25%

25%


* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.                                                                                                                                                    

Source: Pharmarket sales statistics 1-6/2021

Published on 27 April 2021

Review of the Finnish human pharmaceuticals market

Finland is the most important individual market for Orion, generating more than a quarter of the Group's net sales. According to Pharmarket statistics (1–3/2021), the total sales of Orion's human pharmaceuticals in January-March 2021, including both medicinal and non-medicinal products, declined faster than the market. The overall market decline is largely explained by a strong comparative period, during which COVID-19 increased demand notably. The prevalence of seasonal illnesses such as the common flu has been lower than normal due to which the market volumes were lower than normal especially in the self-care products.

Orion's biggest product group in Finland are reference-priced prescription drugs in the pharmacy channel. The sales of Orion's reference-priced prescription drugs fell from the review period slower than the market. The average price of reference-priced drugs in the market declined approximately 5% from the comparative period (Source: Pharmarket). The impact of constant price competition on Orion has been significant due to the Company's broad product range and significant market share in Finland.

Despite the challenging operating environment, Orion has maintained its position as leader in marketing pharmaceuticals in Finland. Orion has a particularly strong position in reference-priced prescription drugs and self-care products, with its market share being a quarter of the market in each.

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

 

EUR million

 

1-3/21

1-3/20

Change %

Total sales of human pharmaceuticals (hospital and pharmacy channel)

 

 

 

Market

 

698

750

-7%

Orion

 

75

86

-13%

Prescription drugs total (pharmacy channel)

 

 

 

 

Market

378

398

-5%

Orion

43

46

-8%

Reference priced prescription drugs (pharmacy channel) *

 

 

 

Market

101

113

-10%

Orion

25

27

-7%

Self-care products (pharmacy channel)

 

 

 

Market

 

100

119

-16% 

Orion

 

25

30

-18% 

 

* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.

   

Source: Pharmarket sales statistics 1-3/2021

 

Orion’s market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

 

Orion’s market share, %

1-3/21

1-3/20

Human pharmaceuticals in total (hospital and pharmacy channel)

11%

11%

Prescription drugs total (pharmacy channel)

11%

12%

Reference priced prescription drugs (pharmacy channel) *

24%

24%

Self-care products (pharmacy channel)

25%

26%


* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales and market share figures in the comparative period may deviate from previously published data.                                                                                                                                        

Source: Pharmarket sales statistics 1-3/2021